SOURCES SOUGHT
65 -- Genomics reagent supplies
- Notice Date
- 6/19/2018
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Clinical Center/Office of Purchasing & Contracts, 6707 Democracy Blvd, Suite 106, MSC 5480, Bethesda, Maryland, 20892-5480
- ZIP Code
- 20892-5480
- Solicitation Number
- 18-012476
- Archive Date
- 6/29/2018
- Point of Contact
- Priscilla S. Abalos, Phone: 3015943879
- E-Mail Address
-
priscilla.abalos@nih.gov
(priscilla.abalos@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Solicitation # HHSN-NIH-CCOPC-SBSS-18-012476 This is a Small business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources:(2) whether there are small businesses, HUBZONE small businesses, service disabled veteran-owned small businesses or (8a) small businesses, veteran- owned small business, woman-owned small businesses or small disadvantaged businesses veteran owned small businesses; woman owned businesses, or small disadvantaged businesses and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable code should not submit a response to this notice. Background Information The Department of Transfusion Medicine (DTM) core Next Generation Sequencing (NGS) research lab is prioritized to be established with the following objectives- • Characterization of emerging cell therapy products to improve safety, purity, potency, stability and efficacy. • To advance the nascent development and science of red cell genotyping. • For development and molecular validation of red cell antigen expression algorithms to improve transfusion safety. 1. Type of product or service to be acquired; The Department of Transfusion Medicine (DTM) core Next Generation Sequencing (NGS) research lab is prioritized to be established with the following objectives- • Characterization of emerging cell therapy products to improve safety, purity, potency, stability and efficacy. • To advance the nascent development and science of red cell genotyping. • For development and molecular validation of red cell antigen expression algorithms to improve transfusion safety. In order to ensure further analysis of safety prior to clinical scale use of experimental therapies, the DTM NGS core facility is being developed to research newer technologies to be incorporated into patient care. As part of this goal, we intend to purchase the 10x genomics single cell seperator for sample preparation prior to clinical use. We also intend to use the equipment for red cell genomics and analysis with our research core facility. 2. Explanation for how the agency intends to use the product or service in terms of function to be performed; and As part of cellular therapy manufacturing and red cell genomics services, the DTM/CPS also offers core research support, including new research technologies to measure cellular safety, purity, potency and consistency and for red cell genotyping. Traditional assays which are based on flow cytometry and serology only provide superficial information about cell quality and red cell phenotype prior to infusion. Hence improved methods are needed to perform additional analysis prior to using these expensive experimental therapies in humans. The 10x genomics single cell separator provides a simple, sophisticated, and sensitive method of identifying ane separating single cells for high resolution analysis for research and clinical characterization. 3. Performance requirement or essential physical characteristics. In order to operate at optimal levels and incorporate novel research technologies for clinical use, the following attributes of the 10x single cell seperator are critical for high resolution cell characterization. Generate single-cell transcript counts from up to 100,000 cells per run. Produce >90,000 individual nanoliter-scale partitions leveraging ~750,000 unique 16 bp Barcodes, Capture cells at high efficiency up to 65%, Low doublet rate 0.9% per 1,000 cells, Achieve deep profiling of complex cell populations with high-throughput digital gene expression of individual cells, Provide stand-alone, turn-key analysis pipelines and visualization software for novice and expert users alike, Include a microfluidics chip that is compatible with a wide range of eukaryotic cell sizes, and types (e.g. adherent cell cultures, suspension cell cultures, tissues, blood, etc.), Rapid time to lysis facilitates an accurate view of the transcriptome with minimal impact on gene expression Delivery Schedule These supplies will be shipped for delivery Monday through Thursday to: NIH/CC/DTM/ 10 Center Drive Bldg. 10/ Rm. 3C720 Bethesda, MD 20892-128 Attention: Sandhya Punch Shipments will use government carrier at the expense of the government unless otherwise arranged. The contractor shall bear the cost of replacement for reagents and disposables found to be damaged or defective upon receipt by NIH or for incorrect or incomplete shipments. Government Responsibilities The Cell Processing Section shall use the reagents and disposables in accordance with manufacturer's package inserts and approved IND/IDE uses if applicable. The NIH CC Cell Processing Section shall inspect shipments upon receipt and report any damage, defects or errors in shipment to the contractor. Capability Statement is to include: Information regarding respondents; (a), including their availability, experience and informal and other training; (b) current in-house capability to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and (e) examples of prior completed Government contracts; references, and other related information: Respondents, DUNS number, organization name, address, point of contract, and size and type of business (e.g.8(a), HUBZone, etc) pursuant to the applicable NAICS code; Respondents; technical and administrative points of contract including names, titles addresses, telephone and fax numbers and email addresses; Respondents must respond to this notice by June 26, 2018 12:00 pm Est DISCLAIMER AND IMPORTANT NOTICES: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After review of the responses received, a pre-solicitation synopsis and solicitation maybe published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a future solicitation. Primary Point of Contact Priscilla Abalos Contract Specialist Phone Number 301/594/5918
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/CCOPC/18-012476/listing.html)
- Place of Performance
- Address: National Institute of Health, 9000 Rockville PIke Bldg 10-3C-720D, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04959840-W 20180621/180619230624-4a94aef05a7211b52d87043bbb1a3c9b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |